Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
Physician's Weekly,
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9…
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9…
Benefits seen across baseline LDL-C levels of 50 to 125 mg/dL Even post-acute coronary syndrome (ACS) patients with low…
Why is cholesterol so much more controversial than the other cardiac risk factors? A review of cholesterol’s troubled and…
By Rhodes…
Scopri le ricette a basso contenuto di colesterolo Il livello di colesterolo è uno dei primi campanelli d’allarme da tenere…
By Rina Mauricio…
The statin hypothesis is that statins reduce cardiac risk more than can be explained by the reduction in LDL cholesterol. That…
NEJM 18 June 2015 Vol…
By: Karin Katz…
NEJM 4 Jun 2015 Vol…
High cholesterol is a key culprit in the development of cardiovascular disease, the leading cause of death in the United States…
As you walk into Mr. R’s room to see if he has last-minute questions about his discharge medications, you can’t believe how…